Final Programme

4th INTERNATIONAL FORUMON MOOD

AND ANXIETY DISORDERS

MONTE-CARLO, NOVEMBER 19-21, 2003

WEB SITE: www.aim-internationalgroup.com/2003/ifmad

SCIENTIFIC AND ORGANIZING SECRETARIATPUBLI CREATIONS - Partner of AIM27, Bd d’Italie - 98000 Monte-Carlo – MonacoPh +377 97973555Fax +377 97973550e-mail: ifmad@publicreations.comWebsite: www.aim-internationalgroup.com/2003/ifmad

CONGRESS VENUEMonte-Carlo Grand Hotel12, Av. des Spélugues98000 Monte-Carlo – MonacoPh +377 93506500Fax +377 93300157

On the cover : M.C. Escher “ The Node ”

It is our pleasure to welcome you in Monte-Carlo to the annual meeting of the International Forum on Mood and Anxiety Disorders(IFMAD).

IFMAD has become an important forum for the exchange of ideas onthe latest developments in psychiatric treatments where internationalexperts can address in an informal atmosphere some of the importanttopics in the field of mood and anxiety disorders. The meetings are par-ticularly valued for the high quality of the scientific contributions andthe opportunity for focused discussion of new data presented in aconstructive and productive environment.

Attendees at previous meetings have appreciated the very efficient andagreeable formula provided by IFMAD meetings for keeping up to datewith current treatment issues. We look forward to renewing oldacquaintances at the next meeting and to welcoming an even wideraudience.

We are pleased to have you with us again this year so that you have theopportunity to keep abreast of the latest advances.

Siegfried Kasper Stuart Montgomery

Chairman Co-Chairman

CHAIRMANSiegfried Kasper (Austria)

CO-CHAIRMANStuart A. Montgomery (United Kingdom)

SCIENTIFIC ADVISERSChrister Allgulander (Sweden)

A. Carlo Altamura (Italy) David Baldwin (United Kingdom)

Graham Burrows (Australia)Joseph Calabrese (USA)

Giovanni B. Cassano (Italy)William F. Deakin (United Kingdom)

Koen Demyttenaere (Belgium)Elias Eriksson (Sweden)Teruhiko Higuchi (Japan)

Robert M.A. Hirschfeld (USA)Sidney H. Kennedy (Canada)Jean-Pierre Lépine (France)

Mario Maj (Italy)Julien Mendlewicz (Belgium)

Hans-Jürgen Möller (Germany)Franz Müller-Spahn (Switzerland)

Philippe H. Robert (France)Alan F. Schatzberg (USA)Dan J. Stein (South Africa)

Trisha Suppes (USA) Eduard Vieta ( Spain)

Lars von Knorring (Sweden)Shigeto Yamawaki (Japan)

Joseph Zohar (Israel)

4 Forum Venue

5 Acknowledgements

6 Programme Overview

7 Scientific Programme

15 Posters

22 Scientific Information

23 General Information

26 Local Information

4

1S

AL

ON

SGR

AND P

RIX

SA

LL

ED

’OR F

OY

ER

PETI

T SA

LON

AB

PE

TIT

SA

LON

SA

LLE

D’O

R 1

- S

lide

Pre

view

- Aud

itoriu

m

FO

YE

R

SA

LON

SG

RA

ND

PR

IX A

& B

- Lu

nch

and

Exh

ibiti

on

- B

reak

fast

5

The Organising Committee espress their gratitudeto the following Companies

ASTRA ZENECABOEHRINGER INGELHEIM and ELI LILLY and COMPANY

H. LUNDBECK A/SJANSSEN CILAG and ORGANON

for their contribution as Sponsors of Symposia

BOEHRINGER INGELHEIM and ELI LILLY and COMPANYMARTIN DUNITZ

MERCK SHARP & DOHMEPIERRE FABRE MEDICAMENT

for their valuable co-operation

WISEPRESS Ltdfor their participation in the publication exhibition

Wednesday, Thursday, Friday,November 19 November 20 November 21

08.30/10.30 08.30/10.30S04 “Recent advances S09 “Controlling

in treatment of placebo”anxiety disorder”

10.30/10.45 10.30/10.45Coffee break Coffee break

10.45/12.45 10.45/12.45S05 “Depression and S10 “Controlling maniaanxiety disorders – the with antipsychotic

importance of fast treatment”and effective treatment”

12.45/13.45 12.45/13.45Lunch Lunch

13.30/15.30 13.45/15.45 13.45/15.45S01 “New bipolar S06 “New treatments S11 “New results antidepressants” for GAD” in mania”

15.30/15.45A European

Depression Day15.45/16.00 15.45/16.00 15.45/16.00Coffee Break Coffee Break Coffee Break

16.00/18.00 16.00/18.00 16.00/18.00S02 “Monotheraphy, new S07 “Pain in psychiatric S12 “New treatment for

experience with disorders” resistant orRisperidone in refractory depression”bipolar disease”

18.00/19.00 18.00/20.00 18.00S03 Plenary Lecture S08 “The neurobiology Closure

“The search for genes of depression: bridgingof bipolar disorder: brain and body to achieve

treatment implications” and retain remission”

PresentationIFMAD Award

19.00/20.00Opening Reception

13.00/18.00 08.30/20.00 08.30/18.00Poster Display Poster Display Poster Display

6

7

Scientific Programme

8

WEDNESDAY, November 19, 2003

13.30 – 15.30S01 NEW BIPOLAR ANTIDEPRESSANTS Chair: J. Angst (Switzerland), H. Aschauer (Austria)

S0101 Are atypical antipsychotics effective in bipolardepression?H. Aschauer (Austria)

S0102 Long term treatment of bipolar depressionG. Evoniuk (USA)

S0103 The switch from depression to hypomania and mania:fact or fiction? J. Angst (Switzerland)

S0104 Continuation treatment for mania: what happens todepression?E. Vieta (Spain)

15.30 – 15.45PRESENTATION OF A EUROPEAN DEPRESSIONDAYM. Selo (Switzerland)President of the Werner Alfred Selo Foundation

15.45 – 16.00Coffee break

9

16.00 – 18.00S02 MONOTHERAPHY, NEW EXPERIENCEWITH RISPERIDONE IN BIPOLAR DISEASEChair: S.Montgomery (United Kingdom)

S0201 The challenge of bipolar disorder for the patient if notproperly diagnosed and treatedE. Vieta (Spain)

S0202 The use of atypical antipsychotics as monotherapy: newevidence for efficacy (short-term)M. Eerdekens (Belgium)

S0203 The use of atypical antipsychotics as monotherapy: newevidence for efficacy (longer term)S. Kasper (Austria)

S0204 Clinical trials vs clinical experience: special patientpopulations, defining the best dosage and best use ofatypical antipsychotics in bipolar disorderS. Montgomery (United Kingdom)

Sponsored by an unrestricted educational grant ofJANSSEN-CILAG and ORGANON

18.00 – 19.00S03 PLENARY LECTURE Chair: S.Kasper (Austria)The search for genes of bipolar disorder: treatmentimplicationsJ. Mendlewicz (Belgium)

Presentation of the International Forum Awardestablished with the generous collaboration of MERCK SHARP & DOHME

19.00 – 20.00Welcome cocktail

10

THURSDAY, November 20, 2003

08.30 – 10.30S04 RECENT ADVANCES IN TREATMENT OFANXIETY DISORDER Chair: M. Bourin (France), E. Eriksson (Sweden)

S0401 Atypical antipsychotics in treating anxiety disordersJ. Zohar (Israel)

S0402 Is PMDD an anxiety disorder?E. Eriksson (Sweden)

S0403 Recent advances in panic disorder M. Bourin (France)

S0404 Recent advances in social phobia C. Allgulander (Sweden)

10.30 – 10.45Coffee Break

10.45 – 12.45S05 DEPRESSION AND ANXIETY DISORDERS – THE IMPORTANCE OF FAST AND EFFECTIVETREATMENTChair: D. Baldwin (UK), W. Burke (USA)

S0501 Priorities in treating depressionW. Burke (USA)

S0502 How can the treatment of depression be optimised?S. Kasper (Austria)

S0503 Escitalopram - a unique mechanism of actionC. Sanchez (Denmark)

S0504 Unmet needs in anxiety disorders - how can we improvetreatment ?D. Baldwin (United Kingdom)Sponsored by an unrestricted educational grant of H. LUNDBECK A/S

12.45 – 13.45Lunch

11

THURSDAY, November 20, 2003

13.45 – 15.45S06 NEW TREATMENTS FOR GAD Chair: S.Montgomery (UK), R. Nil (Switzerland)

S0601 Pregabalin compared with other anxiolytics in GADR. Kavoussi (USA)

S0602 SSRIs in the treatment of GADD. Baldwin (United Kingdom)

S0603 Discontinuation symptoms in SAD or GAD or depressionR. Nil (Switzerland)

S0604 Fast onset of response in GADS. Montgomery (United Kingdom)

15.45 – 16.00Coffee Break

16.00 – 18.00S07 PAIN IN PSYCHIATRIC DISORDERS Chair: C. Allgulander (Sweden), A. Khan (USA)

S0701 Painful physical symptoms in depressionD. Perahia (United Kingdom)

S0702 Pregabalin and neuropathic painR. Kavoussi (USA)

S0703 Animal models and mechanismsC. Sanchez (Denmark)

S0704 Venlafaxine and the control of painA. Partiot (USA)

12

18.00 – 20.00S08 THE NEUROBIOLOGY OF DEPRESSION:BRIDGING BRAIN AND BODY TO ACHIEVE ANDRETAIN REMISSIONChair: S. Kasper (Austria)

S0801 Recognising and diagnosing depression: a paradigm shiftS. Montgomery (United Kingdom)

S0802 Is two better than one? Strategies to achieve remissionS. Kasper (Austria)

S0803 Dual-action antidepressants: the new frontier for thetreament of depressionA. Leuchter (USA)

Sponsored by an unrestricted educational grant ofBOEHRINGER INGELHEIM and ELI LILLYand COMPANY

13

FRIDAY, November 21, 2003

08.30 – 10.30S09 CONTROLLING PLACEBO Chair: A. Khan (USA), S. Montgomery (UK)

S0901 Placebo trials in depression and anxietyA. Khan (USA)

S0902 Rater training, certification and other mythsW. Potter (USA)

S0903 Severity increases assay sensitivityA. Gerebtzoff (Switzerland)

S0904 Better monitoring, better patientsR. Buller (France)

10.30 – 10.45Coffee Break

10.45 – 12.45S10 CONTROLLING MANIA WITHANTIPSYCHOTIC TREATMENTChair: G.B. Cassano (Italy)

S1001 Pharmacology of atypical antipsychotics in maniaL. Pani (Italy)

S1002 Mania treatment: use of atypical antipsychoticsA. Rotondo (Italy)

Sponsored by an unrestricted educational grant ofASTRAZENECA ITALY

12.45 – 13.45Lunch

14

FRIDAY, November 21, 2003

13.45 – 15.45S11 NEW RESULTS IN MANIAChair: J. Loftus (Monaco), E. Vieta (Spain)

S1101 Risperidone in maniaM. Eerdekens (Belgium)

S1102 Quetiapine in maniaM. Brecher (USA)

S1103 Olanzapine in maniaM. Tohen (USA)

S1104 Ziprasidone in treatment of mania in bipolar disorderS. Romano (USA)

15.45 – 16.00Coffee Break

16.00 – 18.00S12 NEW TREATMENT FOR RESISTANTDEPRESSION Chair: J. Scott (UK), J. Tauscher (Austria)

S1201 Augmentation therapy with psychotherapy in resistantdepressionJ. Scott (United Kingdom)

S1202 Are atypical antipsychotics antidepressants?G. Gharabawi (USA)

S1203 SSRI and atypical antipsychotics in bipolar depressionM. Tohen (USA)

S1204 Current status of lithium augmentation in resistantdepression J . Tauscher (Austria)

18.00 – 18.15CLOSURE

15

P01. Borna disease virus in mood disorders and benefit of novel antivi-ral therapyL. Bode1, A. Auer2, D.E. Dietrich3, H. Ludwig 4 (1Robert KochInstitut, Berlin, Germany, 2Psychiatrist in Practice, Linz, Austria,3Medical School of Hanover, Hannover, Germany, 4Free Universityof Berlin, Berlin, Germany)

P02. Risk factors for post traumatic stress disorder after a road trafficaccidentR. Coronas, J.M. Santos, X. Terrades, M. Ramos, G. GarciaPares (Corporació Hospitalària Parc Taulí, Sabadell, Barcelona,Spain)

P03. Pharmacological difference between escitalopram and citalopramT.I.F.H Cremers, B.H.C Westerink (Brainsonline/RuG,Groningen, The Netherlands)

P04. Depletion of serotonin in platelets after sertraline administrationM. Dannawi (Laboratory of Medical Analysis and Research,Tripolis – Lebanon)

P05. Successful treatment of refractory depression by combination ofpredisone with SSRIs.M. Dannawi (Laboratory of Medical Analysis and Research,Tripolis – Lebanon)

P06. Comparison of sexual functioning in patients receiving duloxetineor paroxetine: acute- and long-termP.l. Delgado1, C.H. Mallinckrodt 2, F. Wang2, P.V.Tran2, S.K.Brannan2, M.W. Wohlreich2, D.G. Perahia3, M.J. Detke2,4,5(1Department of Psychiatry, Case Western Reserve University,Cleveland, OH, Usa, 2 Eli Lilly and Company, Indianapolis IN,USA, 3Eli Lilly And Company, Erl Wood, UK, 4Department ofPsychiatry, Indiana University Medical School, Indianapolis, IN,USA, 5Departments of Psychiatry, Mclean Hospital, Belmont, andHarvard Medical School, Boston, MA, USA

16

P07. Duloxetine vs placebo in the prevention of relapse of major depres-sive disorderM.J. Detke1,2, I. Gilaberte1, D.G. Perahia1, F. Wang1, T.C. Lee1,P. Tran1, C. Miner1, S. Montgomery1, (1Eli Lilly and Company,Indianapolis, IN, USA, 2Department of Psychiatry, IndianaUniversity Medical School, Indianapolis, IN, USA)

P08. Open-label pharmacokinetic study of quetiapine plus divalproex inpatients with schizophrenic/schizoaffective disorders or bipolar dis-orderC. L. DeVane1, H. Winter 2, M. A. Smith2 (1Institute of Psychiatry,Medical University of South Carolina, Charleston, SC, USA,2AstraZeneca, Wilmington, DE, USA)

P09. Potentiation of antidepressant treatment in resistant depression: acomparative study of seroquel versus lithiumJ.P. Dorée, S.V. Tourjman, J. Desrosiers, R. Elie, S. Kuniki, C.Vanier (Centre de Recherche Fernand Seguin, Montréal, QC,Canada)

P10. Olanzapine/fluoxetine combination in rapid cycling bipolardisorderS. Dubé1,2, P.E. Keck2, S.W. Andersen1, A.R. Evans1, M. Tohen1,3(1Lilly Research Laboratories, Indianapolis, IN, USA, 2WesternPsychiatric Institute and Clinic, University of Pittsburgh,Pittsburgh, PA, USA, 3Department of Psychiatry, Harvard MedicalSchool/Mclean Hospital, Belmont, MA, USA)

P11. Adjunctive ziprasidone in treatment-resistant depression: pilotstudyD.L. Dunner1, J.D. Amsterdam2, R.C. Shelton3, H. Hassman4,M. Rosenthal5, S.J. Romano6 (1University of Washington, Seattle,WA, USA, 2University of Pennsylvania, Philadelphia, PA, USA,3Vanderbilt University, Nashville, TN, USA, 4ComprehensiveClinical Research CNS, Clementon, NJ, USA, 5BMR Health Quest,San Diego, CA, USA, 6Pfizer Inc, New York, NY, USA)

17

P12. Comprehensive pooled analysis of remission data: venlafaxine vsSSRIs (comparison)R. Entsuah1, C. Nemeroff2, l. Willard 2, M. Demitrack2, M.Thase3, A. Lenox-Smith4 (1Wyeth Research, Collegeville, PA,USA, 2Emory University School of Medicine, Atlanta, GA, USA,3University of Pittsburgh Medical Center, Pittsburgh, PA, USA,4Wyeth Pharmaceuticals, Taplow, UK)

P13. Meta-Analyses of duloxetine in the treatment of MDDB. Fallisard1, M. Lothgren2, D. Perahia3, A. Garcia-Cebrian4(1Département de Santé publique, Hôpital Paul Brousse, Paris,France, 2European Health Economics Ltd, Weybridge, UK, 3EliLilly & Co. Ltd, European Operations Medical, UK, 4Eli Lilly &Co. Ltd, European Health Outcomes Research, UK)

P14. Quetiapine monotherapy for mania associated with bipolar disorderM. Jones, K. Huizar (Pharmaceuticals, L.P, Wilmington, DE,USA)

P15. Factors of profession deficiency in panic disorder with agoraphobiaM. Latas, V. Starcevic (Institute of Psychiatry KCS, Serbia andMontenegro)

P16. Cognitive impairment in late-onset depressionJ. Loftus, G.Colazzo (Service de Géronto-psychiatrie, CentreHospitalier Princesse Grace, Monaco)

P17. Quetiapine combined with lithium or divalproex for the treatmentof acute mania associated with bipolar disorderJ. Mullen, B. Paulsson (AstraZeneca Pharmaceuticals, L.P.,Wilmington, DE, USA)

P18 . Does age of onset affect the course and severity of major depressivedisorder?H. Oskarsson, H. Kolbeinsson, E. Líndal , T.H. Thorgeirsson,J. Gulcher, K. Stefansson, J.G. Stefansson(deCode genetics,Reykjavík, Iceland)

18

P19. Relationship between suicidality and co-morbid disordersH. Oskarsson, H. Kolbeinsson, E. Líndal , T.H. Thorgeirsson,J. Gulcher, K. Stefansson, J.G. Stefansson(deCode genetics,Reykjavík, Iceland)

P20. Escitalopram and venlafaxine XR in the treatment of major depressivedisorder (MDD) in a randomized, double-blind, fixed-dose studyR. J. Bielski1, D. Ventura2, C-C. Chang2, L. Penatzer2 (1SummitResearch Network, 2Forest Laboratories, Inc., MI, USA)

P21. Psychiatric effects of three different interferon subtypes in chronichepatitis patients: a comparisonG.I. Perini1, C. Pavan1, G. Ferri1,2, S. Zanone Poma1, E. DeToni2, L. Chemello2, E. Berardinello2, F. Bergamaschi1, A.Gatta2, P. Amodio2 (1Dept. of Neuroscience-Section of Psychiatry-University of Padova, Italy, 2Dept. of Clinical and ExperimentalMedicine, University of Padova, Italy)

P22. Prazosin effects on specific symptoms in chronic combat traumaPTSDM.A. Raskind1,2, R.F. Barnes1,2, E.R. Peskind1,2, E.C. Petrie1,2,C. Thompson1,2, E. Kanter1,2, A. Radant1,2 (1VA VISN 20 MentalIllness Research, Education and Clinical Center, Seattle, WA, USA,2University of Washington School of Medicine, Seattle, WA, USA)

P23. The role of the R- and S-enantiomers in the efficacy of citalopramversus escitalopramC. Sánchez, K.P. Bøgesø, B. Ebert, E.H. Reines, C. Bræstrup (H.Lundbeck A/S, Valby Copenhagen, Denmark)

P24. Clinical and neurobiological hypothesis in two cases of Cotard syn-dromeM. Sarchiapone, G. Camardese, V. Carli, C. Cuomo, V. Faia,P. Madia, S. De Risio (Institute of Psychiatry, Catholic Universityof Sacred Heart, Roma, Italy)

19

P25. Bibliotherapy - cognitive-behavioral selfhelp in patients with par-tially remitted depressionM. Schlogelhofer1, G. Wiesegger1, U. Bailer1, H. Eder1, U.Itzlinger 1, G. Jorgl1, F. Leisch2, M. Priesch1, A. Schosser1, K.Hornik 2, U. Willinger 1, H.N. Aschauer1 (1University Hospital forPsychiatry, Department of General Psychiatry, Vienna, Austria,2Department for Statistics and Probability Theory, ViennaUniversity of Technology, Austria)

P26. Respiratory and autonomic panic disorder subtypes: clinical corre-lates and response to alprazolam-XRE. Schweizer1, B. Klee2, C. Kremer2 (1University of Connecticut,Farmington, CT, USA, 2Pfizer Inc, New York, NY, USA)

P27. Ziprasidone in mania: 21-day randomized, placebo-controlled trialS. Segal1, R.A. Riesenberg2, K. Ice3, P. English3 (1Segal Institutefor Clinical Research, North Miami, FL, USA, 2Atlanta Center forMedical Research, Decatur, GA, USA, 3Pfizer Global Research andDevelopment, New London, CT, USA)

P28. The speed of onset of action of alprazolam-XR compared toalprazolam-CT in panic disorder D. Sheehan, K. Harnett-Sheehan, A. Raj (University of SouthFlorida, College of Medicine Dept. Psychiatry, Tampa, FL, USA)

P29. Panic cognitions and response to pharmacotherapy of panic disor-der with agoraphobiaV. Starcevic1, C. White2, L. Birner 2, M. Latas2, D. Kolar2(1Nepean Hospital, University of Sydney, Penrith, NSW, Australia,2University of Newcastle, Newcastle, NSW, Australia)

P30. Anxiety and the prevalence of major depressive disordersJ.G. Stefansson1, H. Kolbeinsson1, H. Oskarsson2, E Líndal1,Th. Thorgeirsson3, J. Gulcher3, K. Stefansson3 (1Landspitali-University Hospital Reykjavik, 2Therapeia and 3deCode Genetics,Reykjavík, Iceland)

20

P31. Milnacipran in adolescents suffering from major depression and/ordysthymiaS. Tauscher-Wisniewski1, M.H. Friedrich 1, J. Tauscher2 (Depts.of 1Neuropsychiatry for Children & Adolescents, and 2GeneralPsychiatry, University of Vienna, Austria)

P32. Remission in placebo-controlled trials of duloxetine with an SSRIcomparatorM.E. Thase1, Y. Lu2, M.J. Joliat2, T. Treuer2, M.J. Detke2,3,4(1Department of Psychiatry, University of Pittsburgh MedicalCenter, Pittsburgh, PA, USA , 2Eli Lilly and Company, Indianapolis,IN, USA, 3Department of Psychiatry, Indiana University MedicalSchool, Indianapolis, IN, USA, 4Departments of Psychiatry,McLean Hospital, Belmont, MA and Harvard Medical School,Boston, MA, USA)

P33. Olanzapine versus placebo for relapse prevention in bipolar depres-sionM. Tohen1,2, C. Bowden2, J. Calabrese3, JC-Y Chou4, T. Jacobs1,R.W. Baker1, D. Williamson1, A.R. Evans1 (1ResearchLaboratories, Indianapolis, IN, USA, 2Dpartment of Psychiatry,Harvard Medical School/Mclean Hospital, Belmont MA, USA,3Dept. Of Psychiatry, Case Western Reserve Univ. Univ. Hospitalsof Cleveland, OH, USA, 4NYU School of Medicine, New York, NY,USA)

P34. Olanzapine versus lithium in relapse prevention in bipolar disorderM. Tohen1,2, A. Marneros2 C. Bowden3, R.W. Baker1, A.R.Evans1, G. Cassano4 (1Lilly Research Laboratories, Indianapolis,IN, USA, 2Department of Psychiatry, Harvard Medical School/McLean Hospital, Belmont, MA, USA, 3Department of Psychiatry,University of Texas Health Science Center, San Antonio, TX, USA,4Department of Psychiatry, University of Pisa, Pisa, Italy)

P35. Quetiapine treatment of borderline personality disorderE. Villeneuve, S. Lemelin(Clinique Le Faubourg St-Jean, CentreHospitalier Robert-Giffard, Québec, Canada)

21

P36. Anxiolytic activity of propoten: involvement of GABA in thiseffectT.A. Voronina, G.M. Molodavkin, J.L. Dugina, S.A. Sergeeva,O.I. Epstein (Institute of Pharmacology RAMS, NPF “MateriaMedica Holding”, Moscow, Russia)

P37. Adjunctive ziprasidone for acute bipolar mania: randomized, place-bo-controlled trialR. Weisler1, J. Dunn2, P. English2 (1University of North Carolinaat Chapel Hill, Department of Psychiatry, Raleigh, NC, USA,2Pfizer Global Research and Development, New London, CT, USA)

P38. Onset of improvement in emotional and painful physical symptomsof depression with duloxetine treatmentM.M. Wohlreich1, S.K. Brannan1, C.H. Mallinckrodt 1, M.J.Detke1,2,3, Y. Lu1, J.G.Watkin1, T. Treuer3, G. Tollefson1 (1EliLilly and Company, Indianapolis, IN, USA, 2Department ofPsychiatry, Indiana University Medical School, Indianapolis, IN,USA,3Eli Lilly and Company, Vienna, Austria)

P39. Bright light therapy in seasonal affective disorder – does it suffice?E. Pjrek, D. Winkler, A. Konstantinidis, N. Thierry, A. Heiden,S. Kasper (Department of General Psychiatry, University ofVienna, Vienna, Austria)

P40. Seasonality of birth in seasonal affective disorderE. Pjrek, D. Winkler, J. Stastny, A. Heiden, M. Willeit, A.Konstantinidis, N. Thierry, S. Kasper (Department of GeneralPsychiatry, University of Vienna, Vienna, Austria)

P41. The preliminary report of an outpatient, double-blind, placebo-controlled study comparing 30 mg and 45 mg of nemifitide versusplacebo in major depressionS.A. Montgomery1, J.P. Feighner2, L. Sverdlov2 (1ImperialCollege, London, UK; 2Innapharma, Park Ridge, USA)

22

Audio-Visual FacilitiesEquipment for computerised Power Point presentations is provided duringthe scientific sessions. Floppy disks and Cd-Rom for Power Pointpresentations can be tested prior to presentation in the slide preview room.Floppy disks or Cd-Rom must be handed over to the Slide preview Roomat least forty minutes before the beginning of the sessions and must becollected directly by the speakers at the end of the session.It is essential forthe smooth running of the sessions that all speakershand in their Power Point presentation in due time.

European Accreditation Following accreditation by EACCME, 15 credits have been granted inorder to allow participants to validate the credits obtained at this activityin their own country. Those interested in obtaining these credits arerequired to fill in a special feedback rating form available in the congressbags or at the Secretariat Desk. Each medical specialist should claim onlythose hours of activity that he/she actually spends on the educationalactivity.

Certificate of AttendanceA certificate of attendance is provided on request at the registration deskon the last day of the congress.

PostersAll the accepted abstracts are scheduled for poster presentation. An area(Foyer) has been prepared for poster exhibition for viewing and discussingwith the authors (especially during lunchtime and coffee breaks).Set up and removal times are as follows:Wednesday, November 19 from 09.00 to 11.00Friday, November 21 at 18.15Postersize : cm 150 height - cm 90 baseAuthors should be registered to the congress.

23

Badges

Participants are requested to wear their badge during all forum activitiesand social events. The participants’ registration fee includes admission toall scientific session and exhibition, forum material, welcome reception,coffee breaks and working lunches. Euro 30,00 is charged forreplacement of a lost badge.

Congress badges are distinguished as follows:

Participants : Transparent

Speakers: Blue

Exhibitors: Green

Staff : Red

Congress Venue and Secretariat

The Congress Venue is the Monte Carlo Grand Hotel and all Congressmaterial and documentation are available from the forum registrationdesk located in the foyer of the Hotel.

Opening hours

Wednesday, November 19, 2003 11.00/20.00

Thursday, November 20, 2003 08.00/20.00

Friday, November 21, 2003 08.00/18.00

Coffee breaks and Lunches

During the Congress session breaks, coffee breaks and lunches are served free of charge to all registered participants, wearing Congressbadges.

In alphabetical order

24

ElectricityThe standard voltage in Monaco is 220 V.

LanguageThe official language of the Congress is English. No simultaneous trans-lation is provided.

InsuranceThe Congress organisers cannot accept liability for personal injuriessustained, or for loss or damage to property belonging to Congress partici-pants, either during or as a result of the Congress. Registration does notinclude insurance.

Mobile phonesDelegates are kindly requested to keep their mobile phones in off positionin the Room where the scientific sessions are held.

Smoking PolicyThe 4th International Forum on Mood and Anxiety Disorderswishes tobe a non-smoking congress. Participants are kindly requested to refrainfrom smoking in the congress venue, including exhibition area andrestrooms.

Welcome Cocktail All delegates are cordially invited to attend the Welcome Cocktail of thecongress, which is held on Wednesday, November 19 at 19.00 in thefoyer of the Monte Carlo Grand Hotel

25

Useful Telephone Numbers:Ambulance and Fire Services Ph +377 93301945 and 18

Police Ph +377 93153015 and 17

Monaco Hospital Ph +377 97989769

26

What to do in Monaco

Sites and attractionsThe Principality has many interesting attractions: the Exotic Gardens, theJapanese Gardens situated right alongside the Mediterranean, and also thetourist train which will take you to explore the streets of Monaco. Visitthe Old town where you can discover, in the narrow medieval alleyways,the Picturesque Place of Saint Nicolas and placette Bosio, the Cathedral,the Prince’s Palace and the Changing of the Guards which takes placeevery day at 11:55.

Museums• The Oceanographic Museum dedicated to Marine science and rare spe-

cies of fish• The Wax museum depicting the history of Monaco’s princes and scenes

from the Grimaldi dinasty• The Exhibition of H.S.H. the Prince of Monaco’s Private collection of

Classic cars: a collection of around 100 vehicles of all ages • The Museum of Napoleonic Souvenirs: a collection of objects and

documents relating to the 1st Empire• The Naval Museum displaying over 180 models of famous boats• The Museum of Prehistoric Anthropology with its collection of human

and extinct animal remains from the archeological excavations of theregion

But also outdoor sporting activities are enjoyed thanks to a very mildclimate• Tennis in the unique setting of the Monte-Carlo Country Club• Golf on the 18 hole course of the Monte-Carlo Golf ClubAnd finally the pleasure of shopping in the excellent choice of storespresent in the Principality: whether you are looking for clothes, orsouvenirs, there are shopping centres and designers shops to satisfy alltastes.

ER

S N

ICE

ICE

AV

EN

UE

PA

ST

EU

R

AV

EN

UE

PA

ST

EU

R

ULE

VA

RD

CH

AR

LES

III

BO

UL

EV

AR

D C

HA

RL

ES

III

SCALDES PI

SSARELLES

ES

CA

L. D

EF

ON

TV

IEIL

LE

PL

AC

ED

U

CA

MP

AN

IN

PL

AC

E

CA

NT

ON

R. D

U C

AMPA

NIN

ES

CA

L. D

ES

SA

UN

ES

R

OUTE

DELA

MOYE

NNE

CORN

ICHE

AVENUE

RU

E

DU

G

AB

IAN

DE

F

ON

TV

IEIL

LE

R. D

E L

'IND

US

TR

IE

P D

'AIL

PO

RT

DE

FON

TVIE

ILLE

AV

. PR

INC

E H

ÉR

ÉD

ITA

IRE

ALB

ER

T

AVENUE

AV. D

ES G

UELF

ES

DE

S

CASTE

LANS

AVENUE

DES

PAPA

LINS

DES

SANB

ARBA

NI

QUAI

RU

E D

E L

A C

OLL

E

FO

NT

VIE

ILL

E

P

P

PP

P

PP

P

P

P

P

P

P

P

P

P

P

P

P

P

PP

P

BE

AU

SO

LE

IL

RO

QU

EB

RU

NE

SA

INT

-RO

MA

N

MO

NA

CO

-VIL

LE

PO

RT

HE

RC

ULE

LELA

RV

OTT

O

AN

SE

DU

PO

RT

IER

PL

AG

ES

DU

L

AR

VO

TT

O

RÉ

SE

RV

ES

OU

S-M

AR

INE

DE

MO

NA

CO

LA

VIG

IE

PO

INT

E D

E L

A P

OU

DR

IÈR

E

MO

NE

GH

ET

TI

RU

EH

ONO

RELABANDE

AVE

NU

EH

EC

TO

R-O

TT

O

BOUL

EVAR

DDU

JAR

DIN

EX

OT

IQU

E

BOULEVARD

DEBE

LGIQ

UE

RUEPLATI

RUE

AV

EN

UE

CR

OV

ET

TO

RUE

BIOV

ÈS

PLATI

RU

E

BOSI

O

BOUL

EVA

RD

DU

JARDIN

EX

OT

IQU

E

ROUTE

DE

LAM

OY

CO

RN

IC

AVEN

UE

PRINCESSE

GR

AC

E

BO

UL

EV

AR

DD

ULA

RV

OTT

O

RU

ED

ES

GIR

OFL

ÉES

AV.S

AIN

T-R

OM

AN

CHEMIND

ELACA

LLAD

A

BOUL

EVA

RD

DU

TÉ

NA

O

CH

EM

IND

ES

OE

ILLE

TS

AV

.DE

L'A

NNO

NCIADE

LACETS

ST

LÉO

N

BD

DU

TÉ

NA

O

TE

NA

O

DE

SC

EN

TE

DU

TÉ

NA

O

DE

SC

EN

TE

DU

LA

RV

OT

TO

DE

SC

EN

TE

DE

S M

OU

LIN

S

BO

UL

EV

AR

DD

UL

AR

VO

TT

O

BO

UL

EV

AR

DD

'ITA

LIE

PLA

CE

DE

S M

OU

LIN

S

ES

CA

LIE

RS

DE

L'IN

ZE

RN

IA

AV.S

TLA

UR

EN

T

RUE

ST

JEA

N

BO

UL

EV

AR

DD

'ITA

LIE

AV

EN

UE

DU

GÉ

NÉ

RA

LD

EG

AU

LL

E

BD

DU

GÉ

NÉR

AL

LE

CLE

RC

AV

EN

UE

DE

GR

AN

DE

-BR

ET

AG

NE

BO

UL

EV

AR

D

DE

S

MO

UL

INS

AV

. SA

INT

CH

AR

LES

AV

EN

UE

DU

MA

RE

CH

AL

FO

CH

BD

.D

EF

RA

NC

E

AV. STE CÉCILE

PL

AC

E D

E L

AC

RÉ

MA

ILL

ÈR

EP

LA

CE

DU

CR

ED

IT L

YO

NN

AIS

PA

SS

AG

ED

OD

A

RU

EP

AR

AD

ISR

UE

DE

SR

OS

ES

AVEN

UEDE

ROQUEVILLE

RUE

BE

LLE

VU

E

RUE

BEL

RE

SP

IRO

PLA

CE

DU

PA

LAIS

PR

OM

EN

AD

ES

TE

BA

RB

E

R. COL. BELLA

NDODE CASTRO

RUE

DE

L'EG

LISE

RU

ED

EL'

AB

BA

YE

R.STEDÉVOTE

AV.

DES

PIN

S

RUE

DES

REM

PA

RTS

R.ND

DELO

RETT

E

R.PH

I.FLO

RENC

RU

EPS

SEM

AR

IED

ELO

RRAI

NE

AV

EN

UE

SA

INT-

MA

RTI

N

CH

EM

IND

ES

PÊCH

EURS

AVEN

UE

DE

LAQ

UAR

ANTA

INE

AV

EN

UE

DE

LA

PO

RTE

NEU

VE

QU

AI A

NTO

INE

1er

QUAIAL

BERT1e

r

RUE

SAIG

E

R.DE

SAC

ORES

R.TE

RRAZ

ZANI

RU

ED

EM

ILLO

PLA

CE

D'A

RM

ES

R.SU

FFRE

N

REYM

OND RU

ELO

UIS

NOTA

RI

RUE

GRIM

ALDI

R.DE

SORA

NGER

S

RUE

DES

PRIN

CES

RUE

BARO

N

RUEDE

LATU

RBIE

RUE D

U ROC

HER

AV.PRINCE

BOUL

EVAR

DALB

ERT1

er

QU

AIA

LBER

T1e

r

RU

EG

RIM

AL

DI

PLA

CE

Ste

DÉ

VO

TE

BO

ULE

VA

RD

RA

INIE

RIII

RUEVOURETTE

CH

EM

IN

DELA

TURBIE

IMPA

SSE

DES

CARR

IÈRE

S

RU

ED

ES

GÉ

RA

NIU

MS

PR

INC

ES

SE

RUE

DU

PORTI

ER

BOUL

EV

ARD

DU

LAR

VO

TTO

RUEDE

SOR

CHI

DÉES

R.AUG.V

ENTO

PI

ERRE

DEMO

NACO

AVEN

UEDU

PO

RT

IMPA

SSE

ET E

SC. D

U

CA

STEL

LER

ETTO

AVENUEPRINCESSE

ALICE

AV

. DE

MO

NT

E-C

ARLO

AVE

NU

ED'

OST

END

E

AV. DE L'HE

RM

ITA

GE

PLA

CE

DU

CA

SIN

O

R.

BE

AU

X-A

RT

S

BOUL

EVA

RD

LOU

ISII

ALLÉEDES

BOULINGRINS

RUEDESIR

IS

AV

ENUE

GA

LE

RIE

CH

AR

LE

S II

I

AVEN

UE

DE

LA

CO

ST

A

N

AV.D

ESCI

TRON

NIER

S

AV. DES SPÉLUG UE S

AVENUEDELAMADON

E

R. H. DU

NANT

BO

UL

EV

AR

DD

'ITA

LIE

CH

.DU

TÉN

AO

.

HE

LIP

OR

T

CH

AN

TIE

R “

DIG

UE

DU

LA

RG

E”

P

P

R.PR

INC.

ANTO

INET

TE

RUE

PRIN

CESS

EFL

ORES

TINE

BO

UL

EV

AR

DR

AIN

IER

IIIP

RUE

LANG

LÉ

STESU

ZANN

E

BOU

LEV

AR

DD

EB

ELG

IQU

E

1

2

3

4

5

67

19

14

1311

12

8

9

1518

10

17

8

11i

5

7

3

1

221

2320

1615

10

9

BR

ET

ELL

EA

UR

EG

LIA

AVENUE D'ALS

ACE

BO

UL

EV

AR

D

BOULEVARD

DE

SU

ISSE

BO

UL

EV

AR

D

RAINIER

III

CB

AD

EF

GH

JK

LM

N

1716

18

22

P

P

1A

utom

obile

Clu

b (E

3)

2B

iblio

thèq

ue L

ouis

-Not

ari (

D3)

3C

apita

iner

ie d

u P

ort H

ercu

le (

F3)

6, Q

uai A

ntoi

ne 1

er

4C

apita

iner

ie d

u P

ort d

e F

ontv

ielle

(C

5)

5C

entr

e de

Con

grès

Aud

itoriu

m (

G4)

6C

entr

e de

Ren

cont

res

Inte

rnat

iona

les

(F3)

7T

héât

re P

rince

sse

Gra

ce (

F3)

8G

rimal

di F

orum

(J3

)

9C

entr

e H

ospi

talie

r P

rince

sse

Gra

ce (

A2)

10C

onse

il N

atio

nal (

C5)

11D

irect

ion

du T

ouris

me

et d

es C

ongr

ès (

G2)

12E

spac

e F

ontv

ieill

e “C

hapi

teau

” (B

5)

13G

are

de M

onac

o-M

onte

-Car

lo (

C3)

14H

élip

ort d

e M

onac

o (B

5)

15M

airie

(D

5)

16M

inis

tère

d'É

tat (

D5)

17M

onte

-Car

lo S

port

ing

Clu

b (L

3)

18O

ffice

des

Em

issi

ons

de ti

mbr

es-p

oste

(C

3)

19P

alai

s de

Jus

tice

(C5)

20P

olic

e M

ariti

me

(E5)

21P

olic

e S

ûret

é P

ubliq

ue (

D3)

22S

port

ing

d'H

iver

(G

3)

23Y

acht

-Clu

b (E

5)

ÉQ

UIP

EM

EN

TS

SP

OR

TIF

SA

Sta

de L

ouis

II (

A4)

BM

onte

-Car

lo B

each

(N

3)

CM

onte

-Car

lo C

ount

ry-C

lub

(N3)

DS

tade

Nau

tique

Rai

nier

III (

D3)

ETe

nnis

Clu

b de

Mon

aco

(C2)

Mon

te-C

arlo

Gol

f Clu

bLa

Tur

bie

(Mon

te-A

gel)

JAR

DIN

S P

UB

LIC

SA

Jard

ins

du C

asin

o (G

3)

BJa

rdin

s du

Lar

votto

(J3

)

CJa

rdin

Jap

onai

s (H

3)

DJa

rdin

s S

aint

-Mar

tin (

C5)

EP

arc

Pay

sage

r de

Fon

tvie

ille

etR

oser

aie

Prin

cess

e G

race

(B

5)

FP

arc

Prin

cess

e A

ntoi

nette

(C

2)

PLÉ

GE

ND

ES

DE

S S

YM

BO

LE

S

Asc

ense

urs

publ

ique

s

Par

king

s pu

blic

s

Par

king

aut

ocar

s

Sta

tions

de

taxi

s

Bur

eaux

de

Pos

te

Rue

pié

tonn

e

P

CE

NT

RE

S A

TT

RA

CT

IFS

ET

CU

LTU

RE

LS

1C

asin

o -

Sal

le G

arni

er (

G3)

2C

athé

dral

e (C

5)

3C

entr

e d'

Acc

limat

ion

Zoo

logi

que

(C3)

4É

glis

e S

aint

e-D

évot

e (E

2)

5H

isto

rial d

es P

rince

s de

Mon

aco

(D4)

(Mus

ée d

e C

ires)

6Ja

rdin

Exo

tique

et G

rotte

de

l'Obs

erva

toire

(B

2)

7M

usée

d'A

nthr

opol

ogie

Pré

hist

oriq

ue (

B2)

8M

usée

Océ

anog

raph

ique

et A

quar

ium

(D

5)

9M

onte

-Car

lo S

tory

(D

5)(S

pect

acle

en

mul

tivis

ion)

10M

usée

Nat

iona

lP

oupé

es e

t aut

omat

es d

'aut

refo

is (

J2)

11M

usée

des

Sou

veni

rs N

apol

éoni

ens

et c

olle

ctio

n de

s A

rchi

ves

His

toriq

ues

du P

alai

s (C

4)

12M

usée

du

Vie

ux M

onac

o (C

4)

13P

alai

s P

rinci

er -

Pla

ce d

u P

alai

sG

rand

s A

ppar

tem

ents

(en

été

seu

lem

ent)

(C

4)

14S

tade

Lou

is II

(A

4)

15T

héât

re d

u F

ort A

ntoi

ne (

E5)

16M

usée

de

la M

arin

e (B

3)

17M

onac

o To

p C

ars

(Mus

ée d

e l'A

utom

obile

)

18M

usée

de

la C

hape

lle d

e la

Vis

itatio

n (D

5)

19M

usée

des

Tim

bres

et d

es M

onna

ies

P

19

P

PP

PO

INT

E D

EL

A V

EIL

LE

AB

D

E

F

A

B

C

D

E

PO

INT

ES

TE

BA

RB

E

MO

NTE

-CA

RLO

VER

SM

EN

VER

SM

E

P

P

STM

ICH

EL

CH

AR

LO

TT

E

RU

EP

RIN

CE

SS

EC

AR

OLI

NE

RU

E

BOS

IO

RUE

IMBE

RTY

P

C

PG

RA

CE

AV

EN

UE

PR

INC

ES

SE

AV

EN

UE

PR

INC

ES

SE

GR

AC

E

PQ

UAI

DES

ETAT

S-UN

IS

AVEN

UE

JOHN

KENN

EDY

P

P

14

12

4

RUE

COMT

EFÉ

LIXGA

STAL

DI

P

RUE E

MILE D

E LOT

H

PLA

CE

DE

LA

VIS

ITA

TIO

N

PLA

CE

DE

LA

MA

IRIE

13

P

P 6

P

LA C

ON

DA

MIN

E

• Ta

xis

Tél

. 93.

15.0

1.01

Age

nce

Com

mer

cial

e M

onac

o Te

leco

m (

B3)

AD

RE

SS

ES

UT

ILE

S

IMPASSEDELAFONTAINE

RUE B

ASSE

ALLÉ

EDA

GHI

LIEV

ANNOUNCEMENTOF NEXT FORUM

The 5th International Forumon Mood and Anxiety Disorders

will be held in Monte-Carlo,November 18-20, 2004

Publi Créations - Partner of AIM

27, Bd. d’Italie - Monte Carlo - MC 98000 (Principality of Monaco)Ph. +377 97973555 - Fax. +377 97973550

E-mail : ifmad@publicreations.com

Cipralex®– Fast, Effective and excellent Tolerability

Ref.: Jack Gorman et al. Efficacy comparison of escitalopram and citalopram in thetreatment of major depressive disorder: Pooled analysis of placebo-controlled trials.CNS spectrums; 2002; 7 (suppl 1): 40-44. Ulla Lepola et al. Escitalopram (10-20mg/day) is efective and well tolerated in a placebo-controlled study in depression inprimary care, Int. Clin. Psychopharmacology, 2003; 18; 211-217.

Cipralex® Abbreviated Prescribing Information Presentation: “Cipralex®”, tablets containing 10 mg escitalopram (as oxalate).Indications: Major depression. Panic disorder with or without agoraphobia. Dosage:Usual dose 10 mg once daily. Maxinum dose 20 mg/day. In the elderly (>65 years), inpanic disorder patients and in patients with reduced hepatic function an initial dose of5 mg/day is recommended. Caution in patients with severely reduced renal function.Not recommended in children and adolescents (